Since 2003, Claudia Barth, MD, has held the following positions:

Chief Medical Officer and Member of the Management Board of the KfH Kuratorium für Dialyse und Nierentransplantation (Curatorium for Dialysis and Renal Transplantation). The KfH was founded in 1969 and serves as a non-profit organization for roughly 1/3 of the German dialysis population, covering 200 kidney centers for adults and 15 kidney centers for children and adolescents. Claudia Barth is in charge of all quality assurance aspects in medicine, implementation of new concepts of medical care, quality assurance in nursing care, pharmacovigilance, regulatory aspects in providing care for dialysis and kidney patients, as well as public relations.

Furthermore, she is Chief Medical and Technical Officer (board member) of the GML AG, which provides full technical service for hospitals/ dialysis centers, as well as care for kidney patients in kidney centers in the Netherlands.

Since 2005, she has been head of the KfH Foundation for Preventive Medicine. This non-profit foundation supports clinically oriented research into kidney disease and its risk factors, in order to prevent the progression of kidney disease towards dialysis.

Claudia Barth is specialized in internal medicine and nephrology. She received her medical training at the University Hospital of Cologne and a degree in health economics at the European Business School of Oestrich/Winkel (Germany). In addition, she holds an associate professorship in internal medicine at the University Hospital of Cologne.

Her research expertise in basic science is in transplantation immunology (DFG 3-year research fellowship, Beth Israel Hospital, Harvard Medical School, Boston, research term at the University of Alberta, Edmonton, Canada). Current research focuses on epidemiological data from dialysis patients in the KfH Quality Assurance database.

She gained expertise in the pharmaceutical industry in the position Head of Medical Affairs at the Janssen-Cilag Corporation, Johnson & Johnson, where she conducted clinical trials for biotech products.

She gained her MD degree from Hannover Medical School in Hannover, Germany, and was a participant in the BMEP program 1985/1986 at Tufts Medical School, Boston and Albert Einstein College of Medicine, New York City, USA, with a grant from the DAAD. She now serves on the advisory board of the IALS. She is a member of different scientific and medical advisory committees with a focus on nephrology, patient safety and concepts of care.